Bei Akademie registrieren
EXEL, US30161Q1040

Exelixis stock: Q3 revenue rises to USD 658.7 million

Published on 11/03/2026 at 22:55 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Exelixis stock enters focus after stronger quarterly sales and earnings. Investors are watching the cancer drug pipeline and its regulatory milestones.

Quarterly results and pipeline milestones

  • Exelixis posted higher third-quarter revenue and GAAP net income for the period ended September 30, 2026.
  • The FDA set March 3, 2027 as the target action date for zanzalintinib in previously treated metastatic colorectal cancer.
  • Management expects topline results from the STELLAR-304 trial in the first quarter of 2027.
EXEL, US30161Q1040, Illustration mit AI erstellt.
EXEL, US30161Q1040, Illustration mit AI erstellt.

Exelixis reported third-quarter results on October 29, 2026, with total revenue of USD 658.7 million for the period ended September 30, up from USD 597.8 million a year earlier. The oncology company published the figures in its third-quarter financial release.

GAAP net income rose to USD 218.1 million from USD 193.6 million in the comparable quarter. Diluted GAAP earnings per share were USD 0.85, while diluted non-GAAP earnings per share reached USD 0.94 after excluding stock-based compensation and the related tax effect.

Cabozantinib supports quarterly growth

U.S. net product revenue from the cabozantinib franchise reached USD 604.9 million. CABOMETYX contributed USD 603.2 million and COMETRIQ USD 1.8 million. Exelixis said the increase in product revenue mainly reflected higher sales volume and a higher average net selling price.

For fiscal 2026, the company kept its total revenue guidance at USD 2.500 billion to USD 2.550 billion and its net product revenue range at USD 2.300 billion to USD 2.350 billion. It lowered the expected effective tax rate to 16% to 18%, from the previous range of 21% to 23%, while leaving research and development and selling, general and administrative expense ranges unchanged.

Pipeline milestones shape the outlook

The FDA is reviewing zanzalintinib with atezolizumab for previously treated metastatic colorectal cancer, with a target action date of March 3, 2027. Exelixis said the application does not currently form part of its 2026 revenue guidance.

The company also expects topline results from the phase 3 STELLAR-304 trial in the first quarter of 2027. The study evaluates zanzalintinib with nivolumab in previously untreated advanced non-clear cell renal cell carcinoma.

Exelixis stock traded at 64.55 euros on Lang & Schwarz at 22:54 CET on Tuesday, November 3, 2026. The real-time quote of Exelixis stock reflects the latest available Lang & Schwarz price.

Exelixis company facts

  • Company: Exelixis, Inc.
  • ISIN: US30161Q1040
  • Ticker: EXEL
  • Primary exchange: Nasdaq
  • Lang & Schwarz price: 64.55 euros at 22:54 CET on November 3, 2026

Broader U.S. equity conditions can be followed in the S&P 500 market coverage.

Further developments for investors include the FDA review, clinical readouts and commercial progress. More news and analyses on Exelixis stock.

Disclaimer...
en | US30161Q1040 | EXEL | boerse | 70452945 |